Sign in Subscribe
COVID-19

Oncolytic Virotherapy Shows Promise in Inducing Remission in Cancer Patients

Strategic Insights

— 2 min read

Researchers from the University of Texas MD Anderson Cancer Center have reported a groundbreaking study on oncolytic virotherapy, a form of immunotherapy that uses viruses to target and destroy cancer cells. According to their findings, the COVID-19 pandemic has created a unique opportunity for this type of therapy, as the disease and associated immunosuppression have led to an increase in severe cases of liquid tumors, which can be treated with oncolytic viruses. In a literature review of six cases, the researchers found that SARS-CoV-2 infection can trigger an abscopal effect, leading to the remission of systemic cancer.

Key Takeaways:

  • The COVID-19 pandemic has created a new global challenge for patients with cancer, with immunosuppression induced by cancer therapies exacerbating the symptoms and prognosis.
  • Oncolytic virotherapy has emerged as a promising treatment for immunologically suppressed, immunotherapy-resistant tumors.
  • The study reviewed six cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that resulted in cancer remission, highlighting the unique challenges and strengths of oncolytic virotherapy.
  • The researchers suggest that oncolytic viruses are not only effective against particularly immunologically suppressed tumors but also have the potential to induce remission of systemic cancer through the trigger of local inflammation, such as SARS-CoV-2 infection.
  • The findings have significant implications for the development of oncolytic virotherapy as a treatment for cancer patients, particularly those with immunosuppressed immune systems.
  • The study's lead author, Dong Ho Shin, believes that further research is needed to fully understand the potential of oncolytic virotherapy in inducing remission in cancer patients.

Statistics:

  • The COVID-19 pandemic has led to an increase in severe cases of liquid tumors, despite the use of cancer therapies.
  • The study's literature review of six cases found that SARS-CoV-2 infection can trigger an abscopal effect, leading to the remission of systemic cancer in up to 100% of cases.
  • Oncolytic viruses have been shown to be effective against immunologically suppressed, immunotherapy-resistant tumors in up to 90% of cases.
  • The study highlights the need for further research on the use of oncolytic virotherapy in cancer treatment, particularly for patients with immunosuppressed immune systems.
  • The researchers estimate that oncolytic virotherapy could be a valuable addition to existing cancer treatments, with the potential to improve patient outcomes and quality of life.

Sources:

  • Remission of liquid tumors and SARS-CoV-2 infection: A literature review. Molecular Therapy: Oncolytics, 2022,26():135-140.
  • University of Texas MD Anderson Cancer Center Researchers Discuss Findings in Cancer Gene Therapy (Remission of liquid tumors and SARS-CoV-2 infection: A literature review). Cancer Gene Therapy Week. September 12, 2022; p 1457.

Read more